Big Money Sentiment decreased to 0.89 in Q4 2018. It has change of 0.17, from 2018Q3’s 1.06. The ratio is negative due to Vertex Pharmaceuticals Incorporated positioning: 51 sold and 205 reduced. 64 funds bought positions and 164 increased positions. Investors holded 231.66 million in 2018Q3 but now own 239.68 million shares or 3.46% more.
1832 Asset Mngmt Limited Partnership invested in 699,600 shs or 0.45% of the stock. Marshall Wace Llp accumulated 61,560 shs. Sheets Smith Wealth Mngmt reported 0.14% stake. Sumitomo Mitsui Hldg Incorporated has invested 0.19% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Salem Investment Counselors invested in 0.04% or 1,894 shs. Johnson Invest Counsel Incorporated has 10,032 shs. Chicago Equity Prtnrs Limited Liability Corp reported 18,810 shs or 0.13% of all its holdings. Bluemountain Capital Mngmt reported 29,015 shs stake. Moreover, New Mexico Educational Retirement Board has 0.17% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Lord Abbett Com Limited owns 436,532 shs or 0.26% of their US capital. Wells Fargo & Communication Mn has 0.11% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 1.91M shs. Livforsakringsbolaget Skandia Omsesidigt invested in 0.06% or 2,267 shs. Meag Munich Ergo Kapitalanlagegesellschaft Mbh has invested 0.06% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Doheny Asset Ca accumulated 0.5% or 4,100 shs. Ohio-based Strs Ohio has invested 0.29% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Vertex Pharmaceuticals Incorporated registered $58.43 million net activity with 0 insider purchases and 36 selling transactions since October 1, 2018. 2,445 shs were sold by ALTSHULER DAVID, worth $475,846. Arbuckle Stuart A sold $998,580 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, November 5. The insider LEIDEN JEFFREY M sold $6.01M. Silva Paul M sold $573,182 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 3,007 shs on Thursday, January 17. Another trade for 1,076 shs valued at $207,926 was sold by Graney Thomas. On Tuesday, February 12 $6.32 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s earnings report is anticipated on April, 25., as reported by RTT. Analysts have anticipation on stock’s earnings per share of $0.68. That’s up 25.93 % from last year’s $0.54 earnings per share. This could be $173.85M profit for VRTX assuming the current $0.68 earnings per share will become reality. -32.00 % negative EPS growth is what analysts predict. $1.00 earnings per share was revealed for previous quarter. VRTX hit $185.82 during the last trading session after $4.09 change.Vertex Pharmaceuticals Incorporated has volume of 1.18 million shares. Since March 28, 2018 VRTX has risen 14.60% and is uptrending. The stock outperformed the S&P500 by 10.23%.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

In total 10 analysts cover Vertex Pharmaceuticals (NASDAQ:VRTX). “Buy” rating has 8, “Sell” are 0, while 2 are “Hold”. 80% are bullish. 23 are the (NASDAQ:VRTX)’s analyst reports since October 1, 2018 according to StockzIntelligence Inc. On Tuesday, December 18 the stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Neutral” rating by Guggenheim. On Wednesday, November 28 the firm earned “Buy” rating by H.C. Wainwright. In Wednesday, March 6 report Cowen & Co maintained it with “Buy” rating and $220 target. On Friday, October 26 the company was upgraded by H.C. Wainwright. On Wednesday, March 6 the rating was maintained by Cantor Fitzgerald with “Buy”. On Thursday, October 25 the firm has “Outperform” rating by BMO Capital Markets given. On Monday, February 25 the firm has “Buy” rating given by Oppenheimer. On Wednesday, March 6 the firm has “Buy” rating by Oppenheimer given. On Thursday, October 25 the stock has “Outperform” rating by Raymond James. In Wednesday, March 6 report Needham maintained it with “Buy” rating and $195 target.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases.The firm is worth $47.51 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs.The P/E ratio is 22.97. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

For more Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news announced recently go to: Nasdaq.com, Nasdaq.com, Seekingalpha.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Peek Under The Hood: SPHQ Has 10% Upside – Nasdaq” announced on March 11, 2019, “CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 – Nasdaq” on February 25, 2019, “Vertex files for mixed shelf offering – Seeking Alpha” with a publish date: February 13, 2019, “VRTX Crosses Above Key Moving Average Level – Nasdaq” and the last “Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates – Nasdaq” with publication date: February 05, 2019.